# A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

> **NCT02029924** · PHASE1 · COMPLETED · sponsor: **Adocia** · enrollment: 37 (actual)

## Conditions studied

- Diabetes Mellitus Type 1

## Interventions

- **DRUG:** BioChaperone insulin lispro
- **DRUG:** Humalog®

## Key facts

- **NCT ID:** NCT02029924
- **Lead sponsor:** Adocia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-03
- **Final completion:** 2014-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029924, "A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02029924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*